Sleep is a vital component of overall health, yet one-in-three people suffer from insomnia - a condition recognised as a "health epidemic" by the CDC. Over recent years, our understanding of the profound effects that sleep has on both our physical and mental health has grown significantly. A single night of poor sleep can impact a person's mood, alertness and memory. Long-term sleep deprivation can lead to life-threatening conditions such as cardiovascular disease, obesity and depression. Given these factors, the market for effective insomnia treatments is substantial, estimated to be worth $80bn this year.
SleepCogni has pioneered a patented Active-Biofeedback therapy, delivered through a unique handheld device. This breakthrough therapy was clinically proven in a randomised-controlled-trial with 80 adults, successfully reducing Clinical Insomnia to Non-Clinical Insomnia in just 7 days and increasing total sleep time by 56 minutes.
The aim of this project is develop SleepCogni's paediatric software platform, conduct a clinical trial, real world evidence, of SleepCogni's therapy and platform focusing on SleepCogni's ability to reducing insomnia symptoms among children and adolescents aged between 6 and 16 years.
Sleep is a vital component of overall health, yet one-in-three people suffer from insomnia - a condition recognised as a "health epidemic" by the CDC. Over recent years, our understanding of the profound effects that sleep has on both our physical and mental health has grown significantly. A single night of poor sleep can impact a person's mood, alertness and memory. Long-term sleep deprivation can lead to life-threatening conditions such as cardiovascular disease, obesity and depression. Given these factors, the market for effective insomnia treatments is substantial, estimated to be worth $80bn this year.
Current solutions in the market are fragmented, and clinicians lack comprehensive tools for optimal patient care. The market opportunity lies in this gap -- a robust, user-friendly app that utilises data from proven sleep therapy to enhance patient-clinician communication and improve treatment strategies.
SleepCogni has pioneered a patented Active-Biofeedback therapy, delivered through a unique handheld device. This breakthrough therapy was clinically proven in a randomised-controlled-trial with 80 adults, successfully reducing Clinical Insomnia to Non-Clinical Insomnia in just 7 days and increasing total sleep time by 56 minutes.
The aim of this project is to augment the benefits of our proven therapy by creating a specific paediatric patient and clinician-led app and dashboard with support from Sheffield Children's NHS Foundation Trust. The platform will harness the rich data captured by our therapy device, empowering patients to manage their sleep health more effectively and equipping clinicians with data-driven insights to enhance treatment strategies.
The amount we sleep has been increasingly recognised as having an important impact on our health and well-being. Over recent years we have become increasingly aware of the effects that sleep has on both our physical and mental health. Even one bad night's sleep or late night can affect a person's mood, alertness and memory. The long-term effect of poor sleep can cause a range of life-threatening conditions such as cardiovascular disease, obesity and depression.
However, insomnia is a global epidemic affecting up to 25% of children and 35% of adolescents with 43% suffering with insomnia into adulthood (Fernandez-Mendoza, 2022).
Our mission is to rid the world of addictive sleeping tablets and provide a good night's sleep for everyone, improving health and well-being.
SleepCogni has identified an urgent clinical need for a solution to support children due to the current lack of treatment options. SleepCogni provides an innovative technological solution to this problem. The wearable medical device delivers sleep therapy offering immediate relief when it's needed most. The patented Active-Biofeedback technology delivers personalised therapy and provides unique behavioural insights to make meaningful improvements. This patented technology uses haptic feedback to break the cognitive cycles that prevent sleep. Providing sleep clinicians with an economical and efficient technological solution to manage insomnia.
SleepCogni now seek to develop and incorporate AI into our patented Active-Biofeedback therapy to improve the personalisation and engagement. Through our collaborators, Sheffield Children's NHS Foundation Trust, this will then be tested in children under 18 in a proof of concept trial to determine the efficacy and user experience.
SleepCogni will act as a first-line therapy solution which will directly address the growing waiting lists, helping paediatric patients self-manage their insomnia alongside their family.
The amount we sleep has been increasingly recognised as having an important impact on our health and well-being. Over recent years we have become increasingly aware of the effects that sleep has on both our physical and mental health. Even one bad night's sleep or late night can affect a person's mood, alertness and memory. The long-term effect of poor sleep can cause a range of life-threatening conditions such as cardiovascular disease, obesity and depression. Sleep deprivation was recently identified by Centers for Disease Control and Prevention as a global epidemic.
The economic costs of poor sleep are huge and lead to a staggering annual productivity loss; US $411bn, Japan $138bn, Germany $60bn and UK $50bn. Unsurprisingly, the sleep aid market is global, demanding and growing, and expected to hit $101.9bn by 2023 with 6.5% CARG (RAND Europe, 2016).
Our mission is to rid the world of addictive sleeping tablets and provide a good night's sleep for everyone, improving health and well-being.
SleepCogni has identified an urgent clinical need for a solution that aids diagnostics, provides treatment and monitors adherence. The SleepCogni system provides an innovative technological solution to this problem. SleepCogni has developed and patented a wearable and bedside device designed to be used within a subject's home, which will provide support to sleep clinicians, through longitudinal data, enabling a fully informed diagnosis. It can also deliver a treatment for insomnia using light, sound and tactile cues personalised through a biofeedback system.
Due to their previous Innovate UK grant, SleepCogni has started to generate real momentum. SleepCogni is now (i) a clinically proven treatment, (ii) FDA registered and (iii) has enrolled four sleep clinics for testing. This project would allow SleepCogni to move to the final stage of development, accelerating commercialisation and capitalising on previous investment.
The amount we sleep has been increasingly recognised as having an important impact on our health and well-being. Over recent years we have become increasingly aware of the effects that sleep has on both our physical and mental health. Even one bad night's sleep or late night can affect a person's mood, alertness and memory. The long-term effect of poor sleep can cause a range of life-threatening conditions such as cardiovascular disease, obesity and depression. Sleep deprivation was recently identified by Centers for Disease Control and Prevention as a global epidemic.
The economic costs of poor sleep are huge and lead to a staggering annual productivity loss; US $411bn, Japan $138bn, Germany $60bn and UK $50bn. Unsurprisingly, the sleep aid market is global, demanding and growing, and expected to hit $101.9bn by 2023 with 6.5% CARG (RAND Europe, 2016).
Our mission is to rid the world of addictive sleeping tablets and provide a good night's sleep for everyone, improving health and well-being.
SleepCogni has identified an urgent clinical need for a solution that aids diagnostics, provides treatment and monitors adherence. The SleepCogni system provides an innovative technological solution to this problem. SleepCogni has developed and patented a wearable and bedside device designed to be used within a subject's home, which will provide support to sleep clinicians, through longitudinal data, enabling a fully informed diagnosis. It can also deliver a treatment for insomnia using light, sound and tactile cues personalised through a biofeedback system.
We now seek to optimise SleepCogni's capability of treating insomnia using SleepCogni's patented active biofeedback which is personalised through our artificial intelligence capabilities using the 20 physiological, behavioural and environmental sensors on the SleepCogni devices. We are working with leading experts in social psychology at Sheffield Hallam University to achieve our goal.
SleepCogni is entering a market where current treatment methods come at a substantial cost. Sleep lab testing costs between $1300 to $5000 - for one night. Sleep treatment equipment such as Continuous Positive Airway Pressure (CPAP), machines for sleep apnoea, typically cost $700 to $4000. Through exports and local manufacturing SleepCogni would make a significant impact on the UK economy.
Trouble to fall asleep or waking up in the middle of the night is a problem 1 in 3 around the world face. A lack of sleep leads to unhappiness, reduces performance, increases the risk of accidents and poses severe hazards to health, including cardiovascular disease and cancer. Current treatments for sleep issues do not work or are too costly, and the most frequent treatment, the sleeping pill, is highly addictive and does not provide a long-term solution. We have now developed a credible and innovative solution to the global sleep problem: SleepCogni, the bedside medical device that helps you sleep; integrating the latest scientific insights into sleep. Amongst its many features it provides a technological embedding of a treatment known to improve outcomes for patients with sleep disorders: Cognitive Behavioural Therapy. We now seek to bring this product to market to help the world sleep. To validate SleepCogni’s measurements and user experience we want to first test it in a laboratory sleep setting, before moving on to a placebo-controlled trial to confirm the effectiveness of SleepCogni to improve sleep.
Braintrain2020 Ltd is a drug free, non-invasive electronic sleep aid device which will help insomniacs, stress and anxiety sufferers unwind, relax and switch off a busy mind, making them sleep-ready. Which will mean they fall asleep quicker and enjoy a better quality of sleep.